Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day
Vertex Pharmaceuticals Inc. (VRTX) shares rose 3.48% to $496.83 on a day when the overall stock market declined, with the S&P 500 down 0.43% and the Dow Jones down 1.05%. This increase ended a two-day losing streak, although the stock remains 4.40% below its 52-week high of $519.68. Compared to competitors, Vertex outperformed AbbVie Inc. (up 3.29%), while Krystal Biotech Inc. and Arcturus Therapeutics Holdings Inc. saw declines.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) rallied 3.48% to $496.83 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.43% to 6,878.88 and Dow Jones Industrial Average falling 1.05% to 48,977.92.
The stock's rise snapped a two-day losing streak.
Vertex Pharmaceuticals Inc. closed 4.40% below its 52-week high of $519.68, which the company reached on March 14th.
The stock outperformed some of its competitors Friday, as AbbVie Inc. (ABBV) rose 3.29% to $232.08, Krystal Biotech Inc. (KRYS) fell 0.26% to $275.64, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.08% to $8.23.
Trading volume (1.8 M) eclipsed its 50-day average volume of 1.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled February 27, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-27-26 1638ET
